• E-mail
• Print
• Comment
• Font Size
• Digg
• del.icio.us
• Discuss article

BioCentury and Nature Publishing Group Launch Inaugural Issue of SciBX(TM)

Posted on: Monday, 4 February 2008, 09:01 CST

Nature Publishing Group (NPG) and BioCentury Publications, Inc. today announced the Inaugural Edition of SciBX: Science-Business eXchange, a highly anticipated weekly publication that identifies and evaluates new developments in science and technology that have commercial and investment potential within the biotechnology and pharmaceutical arena.

The Inaugural Edition of SciBX clearly demonstrates how the scientific acumen of NPG and the business intelligence of BioCentury have combined to put new science into the business context. This week's issue describes how University of North Carolina research may point the way for Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) and privately held Trillium Therapeutics Inc. to extend their antibodies from blood cancers into solid tumors and provide new competition for advanced melanoma compounds in the clinic.

SciBX's science-business approach is exemplified by a pathway map showing the players and clinical programs affected by this new finding.

In addition, the Inaugural Edition of SciBx identifies:

 --  How the efficacy of cancer vaccines could be boosted by a University     of Pennsylvania discovery of a target on cancer cells that enables tumors     to evade the immune system.      --  How triangulating gene association studies helped Genmab A/S (OMX: GEN)     build the rationale for its HuMax-TAC antibody in autoimmune     disorders.      --  How a Northwestern University team has improved the speed of Sanger     sequencing by almost three-fold, a boon to the academic research space.      

This in-depth coverage is accompanied by SciBX's unique "Distillery," compiling the week's most important publications affecting biopharma development. "This Week in Therapeutics" highlights ways to predict metastases with microRNAs; potential markers for cardiovascular disease; melanin-concentrating hormone antagonists for treating obesity; and more. "This Week in Techniques" describes particle-based fabrication of high-density peptide arrays; high-speed, single-channel electrophoresis-based DNA sequencing on a chip; a mouse model for identifying morphine analogs; and more.

To create the Inaugural Edition, the independent SciBX editorial and research team read and evaluated hundreds of scientific papers that are published each week in the most frequently cited journals within the fields of biotechnology, life sciences and chemistry. This team, under the direction of Karen Bernstein, Ph.D., Co-Founder, Chairman and Editor-in-Chief of BioCentury, then conducted the in-depth reporting and analysis to elucidate the business context of the findings and identify the next steps required to transform these developments into commercial and patient value.

"The Inaugural Edition demonstrates how SciBX will be the bridge between cutting edge scientific institutions and their partners in the biopharma industry," said Peter Collins, Publishing Director of NPG. "Our team has drilled down through hundreds of new science reports to find the high impact research that the biopharma industry needs to develop new medicines."

The Inaugural Edition is available without charge to readers through the SciBX website, www.scibx.com.

"Every week, SciBX will map how the latest science could affect the progress of hundreds of companies developing new drugs and their partners," noted David Flores, Co-Founder, President and CEO of BioCentury. "Anyone who invests in the biopharma space cannot afford to miss the coverage of these companies and their competitors."

About SciBX

SciBX: Science-Business eXchange is a joint publication from BioCentury Publications, Inc. and Nature Publishing Group that evaluates hundreds of high impact peer-reviewed scientific papers and selects the most commercially relevant findings that merit deeper analysis. Each issue contains Analysis, in-depth articles examining the commercial impact and next steps required to translate the newest developments in the lab into innovative healthcare solutions. This coverage is complemented by The Distillery, a compilation of the most recently published science with commercial implications, including patent and licensing status. SciBX is published weekly in PDF format and e-mailed simultaneously to subscribers throughout the world.

About BioCentury

BioCentury Publications, Inc., independently owned and based in San Carlos, Calif., provides essential biopharma intelligence from five offices in the U.S. and Europe. Over the past 15 years, a global audience of biotech and pharmaceutical executives and investors has benefited from BioCentury's deep knowledge, data-driven analysis, independent perspective and trustworthy content available through the company's publications, online databases and collaborative industry conferences.

With the launch of SciBX, BioCentury provides even deeper analysis and data across the entire biopharma value chain from research through commercialization. The company recently launched its BCIQ(TM) database to provide access to information on more than 4,000 public and private companies, 5,000 biopharma compounds and $200 billion in financings. BCIQ: BioCentury Online Intelligence is just one more reason why BioCentury is BioPharma's Knowledge Center(TM). For more information, visit www.biocentury.com.

About Nature Publishing Group

Nature Publishing Group (NPG) is dedicated to serving the academic, professional scientific and medical communities. NPG's flagship title, Nature, was first published in 1869. NPG also publishes Nature Biotechnology and Nature Reviews Drug Discovery -- the pre-eminent publications for academic and corporate scientists interested in drug discovery -- together with the Nature research journals, Nature Reviews, Nature Clinical Practice and a range of prestigious academic journals including society-owned publications. NPG also provides news content through Nature News and scientific career information and free job postings on Naturejobs.

NPG is a global company with headquarters in London and offices in New York, San Francisco, Washington, DC, Boston, Tokyo, Paris, Munich, Hong Kong, Melbourne, Delhi, Mexico City and Basingstoke. For more information, please go to www.nature.com.

 Media Inquiries Contact: Lana Guernsey WeissComm Partners Email Contact +1 415 946-1073  Grace Baynes Nature Publishing Group Email Contact +44 (0)20 7014-4063  

SOURCE: BioCentury

Source: MARKET WIRE

More News in this Category